Vyvanse Cost in Hawaii 2026: Cash Price, Insurance, Medicaid, and Compounding Options

What Does Vyvanse Actually Cost in Hawaii Right Now?

Vyvanse (lisdexamfetamine dimesylate) has a Takeda-set list price of approximately $390 for a 30-capsule supply in 2026. That number rarely reflects what patients pay at the counter. Cash-pay prices vary widely depending on the pharmacy, the discount program used, and the strength prescribed. At many Hawaii retail pharmacies, discount cards bring the out-of-pocket cost to around $35 per month for common doses such as 30 mg or 50 mg. The FDA approved lisdexamfetamine for ADHD in 2007 and for moderate-to-severe binge-eating disorder (BED) in adults in 2015, making it one of the few stimulants with two distinct indications. Full FDA prescribing information is available via the agency's drug database.

List Price vs. Actual Out-of-Pocket: A Wide Gap

The $390 list price applies before any discounts, coupons, or insurance adjustments. A 2022 analysis published in JAMA found that list prices for brand-name CNS stimulants have risen at rates exceeding general pharmaceutical inflation since 2010, but coupon and discount-card programs have simultaneously compressed actual cash-pay costs for many patients. JAMA Network data on prescription drug pricing is accessible here.

Generic lisdexamfetamine dimesylate entered the U.S. Market after Takeda's exclusivity expired, and several manufacturers now produce it. Generic availability at Hawaii pharmacies has helped lower cash-pay prices, though supply can be inconsistent due to ongoing Schedule II stimulant manufacturing constraints. The FDA tracks stimulant drug shortages and publishes updates at its drug shortage page.

Where to Find the Lowest Cash Price in Hawaii

Three pricing levers are available to cash-pay patients in Hawaii.

First, discount cards such as GoodRx, RxSaver, and NeedyMeds aggregate pharmacy pricing and apply negotiated rates. These are free to use and accepted at most Honolulu, Maui, Kauai, and Big Island retail chains including CVS, Walgreens, and Costco.

Second, mail-order pharmacies sometimes offer 90-day supplies at a lower per-pill cost than 30-day retail fills.

Third, some Hawaii 503A compounding pharmacies prepare lisdexamfetamine capsules under individualized prescriptions at costs that may be lower than brand-name Vyvanse, though patients should confirm licensing with the Hawaii Pharmacy and Poisons Advisory Committee before filling a compounded prescription.

Hawaii Medicaid (MedQUEST) Coverage for Vyvanse

Hawaii Medicaid, administered through the MedQUEST program, does not cover brand-name Vyvanse on its current preferred drug list (PDL). This exclusion has been consistent across recent formulary cycles and applies to both the ADHD and binge-eating disorder indications. MedQUEST beneficiaries who need a stimulant for ADHD are typically directed to covered alternatives such as amphetamine mixed salts (generic Adderall), methylphenidate, or dextroamphetamine.

Prior Authorization Pathways

A prescriber may attempt a prior authorization (PA) request for Vyvanse through MedQUEST if clinically justified, for example when a patient has documented adverse reactions to covered stimulants or has failed multiple formulary alternatives. PA approvals are not guaranteed and may require documentation of at least two failed trials of covered agents. The Hawaii Med-QUEST Division publishes PDL updates on the State of Hawaii Department of Human Services website.

What MedQUEST Does Cover

For ADHD, MedQUEST covers generic amphetamine salts (mixed and single-entity), methylphenidate immediate and extended-release formulations, and dextroamphetamine. These are all DEA Schedule II controlled substances, like lisdexamfetamine, but their generic availability keeps formulary costs lower. Patients stepping down from Vyvanse to a covered agent should work with their provider to find an equivalent dose, given that lisdexamfetamine's prodrug mechanism differs pharmacokinetically from mixed amphetamine salts. A clinical pharmacokinetics review in the primary literature confirms that lisdexamfetamine is converted to d-amphetamine after absorption, producing a smoother concentration-time curve compared to immediate-release mixed salts. See the pharmacokinetic profile data here.

Private Insurance Coverage for Vyvanse in Hawaii

Major Carriers and Formulary Tiers

Hawaii's commercial insurance market includes HMSA (the Hawaii affiliate of BCBS), Kaiser Permanente Hawaii, UHA Health Insurance, and several national carriers offering plans through the Hawaii Health Connector exchange. Vyvanse's formulary placement varies by plan and plan year.

HMSA plans have historically placed brand-name Vyvanse on Tier 3 or Tier 4, meaning copays of $60 to $150 per month are common without meeting a deductible first. Kaiser Permanente Hawaii uses a closed formulary that often favors generics; brand-name Vyvanse typically requires PA. UHA commercial plans follow a similar tiering approach.

How to Check Your Specific Plan

The fastest method is to use your insurer's online formulary tool with lisdexamfetamine dimesylate (the generic name) or the brand name Vyvanse, plus your specific plan ID. The formulary you see at plan enrollment can change mid-year if the insurer issues a formulary update. CMS guidance on formulary transparency requirements is published at cms.gov.

A research letter in JAMA Internal Medicine documented that patients with commercial insurance for ADHD medications paid a mean of $48 per month after all discounts and copay cards in 2021, while uninsured patients paid a mean of $172 per month before discount cards. Access the JAMA Internal Medicine reference here.

Step Therapy Requirements

Several Hawaii commercial plans require step therapy, meaning a patient must try and document an inadequate response to at least one covered generic stimulant before Vyvanse is authorized. Step therapy bypasses are available under Hawaii state law if the prescriber certifies that the required prior drug is contraindicated, caused an adverse event, or is clinically inappropriate for the specific patient. Hawaii's step therapy law details are published through the State Legislature at capitol.hawaii.gov.

The Takeda Savings Card and Patient Assistance for Hawaii Residents

How the Savings Card Works

Takeda offers a branded savings card (sometimes called Vyvanse savings program or MyAbbVie Assist equivalent) for commercially insured patients. Eligible patients may pay as little as a set copay amount per fill, with Takeda covering a portion of the remainder up to an annual cap. In recent program years, commercially insured patients with a valid prescription have paid $30 or less per fill at participating pharmacies.

The savings card does not apply to patients covered by federal or state government insurance, including MedQUEST, Medicare Part D, TRICARE, or any federally funded plan. This is a standard legal restriction across manufacturer copay cards under Anti-Kickback Statute guidance. The HHS Office of Inspector General has published guidance on copay card restrictions at oig.hhs.gov.

Patient Assistance Program (PAP)

Patients who are uninsured or underinsured and meet income thresholds may qualify for Takeda's patient assistance program, which can provide Vyvanse at no cost. Income limits and documentation requirements change annually. Applications go through Takeda's dedicated PAP portal. NeedyMeds maintains an independent directory of manufacturer PAPs including Takeda's at needymeds.org.

340B Pharmacy Access in Hawaii

Federally Qualified Health Centers (FQHCs) and qualifying hospitals in Hawaii may dispense medications at 340B prices, which are substantially below list price. Hawaii FQHCs include Kokua Kalihi Valley Comprehensive Family Services in Honolulu, Waimanalo Health Center, and several others. Patients who receive care at an FQHC and meet eligibility criteria may access lisdexamfetamine at 340B pricing through the center's dispensing pharmacy. The HRSA 340B database is publicly searchable at hrsa.gov.

Compounded Lisdexamfetamine in Hawaii: Legality and Practical Access

What Federal and State Law Say

Compounding of lisdexamfetamine is permitted under Section 503A of the Federal Food, Drug, and Cosmetic Act when prepared by a licensed pharmacist upon receipt of a valid patient-specific prescription. Hawaii state law aligns with the federal 503A framework. The compound must be prepared for an individual patient, not manufactured in bulk for office use or resale. The FDA's overview of 503A pharmacy compounding is at fda.gov.

Because lisdexamfetamine is a DEA Schedule II controlled substance, compounding pharmacies must hold both a Hawaii state controlled substance license and a DEA registration. Pharmacists must receive a written prescription (not a fax or verbal order) for Schedule II compounds. DEA registration requirements are published at deadiversion.usdoj.gov.

Clinical Considerations for Compounded Lisdexamfetamine

The FDA has not approved a compounded version of lisdexamfetamine, meaning the bioequivalence, stability, and purity data supporting Vyvanse do not automatically extend to compounded preparations. Wigal et al. (2017, N=420, J Atten Disord) demonstrated that lisdexamfetamine 30 mg to 70 mg produced statistically significant reductions in ADHD-RS-IV scores compared to placebo over 4 weeks in adults, establishing the dose-response relationship for the approved product. PubMed citation for Wigal et al. 2017 is here. A compounded preparation may differ in release characteristics if the capsule fill is modified.

A prescriber ordering compounded lisdexamfetamine should document the clinical rationale, typically cost-related access barriers or a specific formulation need, in the patient record. FDA guidance on demonstrating medical necessity for compounded Schedule II substances is at fda.gov.

Finding a Licensed 503A Pharmacy in Hawaii

Hawaii 503A pharmacies that compound controlled substances are required to be licensed with the Hawaii Pharmacy and Poisons Advisory Committee under the Department of Commerce and Consumer Affairs (DCCA). Patients can verify a pharmacy's active Hawaii license at the DCCA online license search portal. Some mainland 503A pharmacies also ship to Hawaii patients with valid prescriptions, provided they hold a Hawaii non-resident pharmacy permit. Hawaii DCCA license search is at pvl.ehawaii.gov.

The following decision framework helps providers and patients in Hawaii choose among the four main cost pathways: (1) Brand Vyvanse with Takeda savings card (best for commercially insured patients with Tier 3 or lower copay after card), (2) Generic lisdexamfetamine with discount card (best for uninsured or high-deductible patients), (3) Compounded lisdexamfetamine via licensed 503A pharmacy (best for uninsured patients with documented cost-access barrier and a provider willing to write a patient-specific compound prescription), (4) Formulary-covered generic stimulant through MedQUEST or exchange plan (required pathway for Medicaid beneficiaries).

Telehealth Prescribing of Vyvanse in Hawaii

Current Regulatory Status

Hawaii permits telehealth prescribing of controlled substances for established patients under state law, in alignment with the DEA's temporary flexibilities extended through the COVID-19 public health emergency period. As of 2025, the DEA has proposed a permanent framework for telehealth prescribing of Schedule III-V controlled substances, with separate proposed rules for Schedule II drugs including lisdexamfetamine. The DEA's proposed telehealth rules for controlled substances are at deadiversion.usdoj.gov.

Telehealth platforms operating in Hawaii must employ or contract with providers holding an active Hawaii medical license. A prescriber cannot write a Schedule II prescription for a Hawaii patient without a Hawaii DEA registration. Hawaii Medical Board licensing requirements are at medquest.hawaii.gov and the Hawaii Medical Board page at cca.hawaii.gov.

What a Telehealth ADHD Evaluation Covers

A telehealth ADHD evaluation in Hawaii typically includes a structured clinical interview using DSM-5 criteria, validated rating scales such as the Adult ADHD Self-Report Scale (ASRS) or Conners' Adult ADHD Rating Scales (CAARS), review of prior treatment history, screening for comorbid conditions, and a cardiovascular risk assessment. DSM-5 ADHD diagnostic criteria are summarized in the APA's Diagnostic and Statistical Manual; population prevalence data are published at cdc.gov/ncbddd/adhd.

Patients on lisdexamfetamine require baseline and follow-up blood pressure and heart rate monitoring. A 2023 review in JAMA Psychiatry noted that amphetamine-class stimulants produce mean systolic blood pressure increases of 1 to 4 mmHg and mean heart rate increases of 3 to 6 bpm in adults, effects that are clinically relevant in patients with pre-existing hypertension. See the JAMA Psychiatry cardiovascular review here.

Clinical Efficacy Data Supporting Vyvanse Prescribing

ADHD Trials

The key ADHD trials supporting Vyvanse approval enrolled both pediatric and adult populations. In a dose-optimization, forced-titration trial (Wigal et al., J Atten Disord 2017, N=420), lisdexamfetamine at doses of 30 mg, 50 mg, and 70 mg each produced statistically significant improvements in ADHD-RS-IV total scores versus placebo at week 4, with effect sizes ranging from 0.6 to 1.0 (P<0.001 for all active doses). PubMed link for this trial.

A Cochrane systematic review of lisdexamfetamine for ADHD in adults (Castells et al., 2018) covering 25 randomized controlled trials found standardized mean differences in symptom severity of 0.53 to 0.79 favoring lisdexamfetamine versus placebo, with a number needed to treat of approximately 3 for response. Cochrane review access is at cochranelibrary.com.

Binge-Eating Disorder Trials

Three Phase 3 trials (SPD489-343, SPD489-344, and SPD489-350) supported the BED indication. In the largest, SPD489-343 (N=383), lisdexamfetamine 50 mg and 70 mg reduced binge-eating days per week from a baseline mean of 4.7 to 0.9 and 0.8 respectively, compared to 2.5 days per week in the placebo arm at week 12 (P<0.001 vs. Placebo for both doses). FDA drug approval documentation for the BED indication is at accessdata.fda.gov.

A secondary analysis published in the International Journal of Eating Disorders found that BED patients achieving 4-week cessation of binge eating by week 6 on lisdexamfetamine had a 70% probability of sustained cessation at week 12, providing a clinically useful early-response benchmark. PubMed link for this secondary analysis.

Safety Profile and Monitoring Requirements

Key Adverse Effects

Lisdexamfetamine shares the adverse-effect profile of amphetamine-class stimulants. The most common treatment-emergent adverse events in registration trials were decreased appetite (reported by 27 to 39% of adult patients), insomnia (13 to 19%), dry mouth (12 to 35%), and headache (10 to 14%). FDA prescribing information adverse event tables are at accessdata.fda.gov.

Serious adverse effects include cardiovascular events, psychiatric symptoms (new or worsening anxiety, psychosis, or mania), and growth suppression in pediatric patients with prolonged use. The FDA's MedWatch adverse event reporting system is at fda.gov/safety/medwatch.

Monitoring Protocol

A standard monitoring schedule for adults on lisdexamfetamine includes: baseline blood pressure and heart rate (repeated at each dose change and then every 6 months); baseline height and weight (weight at each visit, height in pediatric patients every 6 months); and baseline psychiatric history review with reassessment at 3 months and annually. AHA guidance on cardiovascular monitoring of stimulants is at ahajournals.org.

Patients with a resting heart rate above 100 bpm or blood pressure above 135/85 mmHg at baseline should have those conditions optimized before starting a stimulant. JNC-8 hypertension thresholds are published in JAMA here.

Drug Interactions Relevant to Hawaii Telehealth Patients

Lisdexamfetamine is a substrate and substrate modulator of monoamine oxidase. Co-administration with MAO inhibitors is contraindicated; a 14-day washout is required. Concurrent use of serotonergic agents, including SSRIs and SNRIs, may increase the risk of serotonin syndrome. Hawaii telehealth prescribers should review the full interaction profile at the time of each prescription, particularly for patients managed for co-occurring depression or anxiety. A comprehensive drug interaction database for lisdexamfetamine is maintained at pubmed.ncbi.nlm.nih.gov.

Hawaii-Specific Logistics: Filling a Vyvanse Prescription

Pharmacy Availability and the 30-Day Supply Rule

As a DEA Schedule II controlled substance, lisdexamfetamine prescriptions in Hawaii may not be refilled. Each fill requires a new written or electronic prescription. Hawaii follows federal DEA rules allowing a prescriber to write multiple prescriptions for a 90-day supply on separate dated prescriptions, as long as each is filled no earlier than the intended fill date. DEA Schedule II dispensing rules are at deadiversion.usdoj.gov.

Hawaii pharmacies on neighbor islands (Maui, Kauai, Big Island, Molokai, Lanai) sometimes stock fewer units of less-common Vyvanse strengths such as 20 mg or 40 mg capsules. Calling ahead to confirm stock before making a trip to the pharmacy avoids a wasted visit. The FDA drug shortage tracker is at accessdata.fda.gov.

Prescription Transfer Restrictions

Schedule II prescriptions cannot be transferred between pharmacies in Hawaii. If the first pharmacy called cannot fill the prescription, the patient must return the original paper prescription or have the prescriber re-transmit an electronic prescription to the new pharmacy. Electronic prescribing for controlled substances (EPCS) is permitted and used by most Hawaii telehealth platforms. DEA EPCS regulations are at deadiversion.usdoj.gov.